Doctors Recommend A New Type Of Flu Vaccine.
A vaccine that protects children against four strains of flu may be more striking than the usual three-strain vaccine, a renewed cramming suggests. The four-strain (or so-called "quadrivalent") vaccine is available as a nasal sprinkler or an injection for the first time this flu season. The injected version, however, may be in blunt supply, according to the US Centers for Disease Control and Prevention. The study of about 200 children did not measure against the four-strain vaccine to the traditional three-strain vaccine.
Rather, it looked at how kids responded either to the four-strain vaccine or a hepatitis A vaccine, and then compared answer rates for the four-strain flu vaccine to reaction rates for the three-strain vaccine from last year's flu season. "This is the victory large, randomized, controlled trial to demonstrate the efficacy of a quadrivalent flu vaccine against influenza in children," said look at co-author Dr Ghassan Dbaibo.
"The results showed that, by preventing middle to severe influenza, vaccination achieved reductions of 61 percent to 77 percent in doctors' visits, hospitalizations, absences from drill and parental absences from work," said Dbaibo, at the sphere of pediatrics and adolescent medicine at the American University of Beirut Medical Center, in Lebanon. The results authenticate the effectiveness of the vaccine against influenza, and particularly against moderate to tough influenza.
"They also showed an 80 percent reduction in lower respiratory tract infections, which is the most common important outcome of influenza. Therefore, vaccination of children in this age group can help to reduce the significant gravamen placed on parents, doctors and hospitals every flu season. The report was published online Dec 11, 2013 in the New England Journal of Medicine.
The look was funded by GlaxoSmithKline, maker of the four-strain vaccine hand-me-down in the study. Dr Lisa Grohskopf, a medical constable in CDC's influenza division, said there are several flu vaccine options for children. For children age-old 2 and up, a nasal spray is an option, and for children under 2, the usual injection is available. "The nasal spread vaccine is a quadrivalent vaccine, which has four different flu viruses in it.
Showing posts with label three. Show all posts
Showing posts with label three. Show all posts
Monday 25 March 2019
Thursday 29 November 2018
Dialysis Six Times A Week For Some Patients Better Than Three
Dialysis Six Times A Week For Some Patients Better Than Three.
Kidney loss patients who increase the number of weekly dialysis treatments typically prescribed had significantly better resolution function, overall health and general quality of life, new dig into indicates. The finding stems from an analysis that compared the impact of the 40-year-old standard of anguish - three dialysis treatments per week, for three to four hours per sitting - with a six-day a week treatment regimen involving sessions of 2,5 to three hours per session. Launched in 2006, the kinship involved 245 dialysis patients assigned to either a conventional dialysis schedule or the high-frequency option. All participants underwent MRIs to assess stomach muscle structure, and all completed quality-of-life surveys.
In addition to improved cardiovascular fitness and overall health, the analysis further revealed that two concerns faced by most kidney failure patients - blood compel and phosphate level control - also fared better under the more frequent remedying program. Dr Glenn Chertow, chief of the nephrology division at Stanford University School of Medicine, reports his team's observations in the Nov 20, 2010 online copy of the New England Journal of Medicine, to tally with a presentation at the annual meeting of the American Society of Nephrology in Denver.
And "Kidneys go seven days a week, 24 hours a day," Chertow esteemed in a Stanford University news release. "You could imagine why people might feel better if dialysis were to more closely reproduce kidney function. But you have to factor in the burden of additional sessions, the make a trip and the cost".
Kidney loss patients who increase the number of weekly dialysis treatments typically prescribed had significantly better resolution function, overall health and general quality of life, new dig into indicates. The finding stems from an analysis that compared the impact of the 40-year-old standard of anguish - three dialysis treatments per week, for three to four hours per sitting - with a six-day a week treatment regimen involving sessions of 2,5 to three hours per session. Launched in 2006, the kinship involved 245 dialysis patients assigned to either a conventional dialysis schedule or the high-frequency option. All participants underwent MRIs to assess stomach muscle structure, and all completed quality-of-life surveys.
In addition to improved cardiovascular fitness and overall health, the analysis further revealed that two concerns faced by most kidney failure patients - blood compel and phosphate level control - also fared better under the more frequent remedying program. Dr Glenn Chertow, chief of the nephrology division at Stanford University School of Medicine, reports his team's observations in the Nov 20, 2010 online copy of the New England Journal of Medicine, to tally with a presentation at the annual meeting of the American Society of Nephrology in Denver.
And "Kidneys go seven days a week, 24 hours a day," Chertow esteemed in a Stanford University news release. "You could imagine why people might feel better if dialysis were to more closely reproduce kidney function. But you have to factor in the burden of additional sessions, the make a trip and the cost".
The Impact Of Rituxan For The Treatment Of Follicular Lymphoma
The Impact Of Rituxan For The Treatment Of Follicular Lymphoma.
New on provides more data that treating certain lymphoma patients with an costly drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly rise life span, raising questions about whether it's worth taking. People with lymphoma who are light of maintenance treatment "really need a discussion with their oncologist," said Dr Steven T Rosen, foreman of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago. The look at involved people with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a span that refers to cancers of the immune system.
Though it can be fatal, most nation live for at least 10 years after diagnosis. There has been debate over whether people with the disease should convoy Rituxan as maintenance therapy after their initial chemotherapy. In the study, which was funded in part by F Hoffmann-La Roche, a pharmaceutical cast that sells Rituxan, roughly half of the 1019 participants took Rituxan, and the others did not. All formerly had taken the drug right after receiving chemotherapy.
In the next three years, the mull over found, people taking the drug took longer, on average, to lay open symptoms. Three-quarters of them made it to the three-year mark without progression of their illness, compared with about 58 percent of those who didn't pirate the drug. But the death rate over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.
New on provides more data that treating certain lymphoma patients with an costly drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly rise life span, raising questions about whether it's worth taking. People with lymphoma who are light of maintenance treatment "really need a discussion with their oncologist," said Dr Steven T Rosen, foreman of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago. The look at involved people with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a span that refers to cancers of the immune system.
Though it can be fatal, most nation live for at least 10 years after diagnosis. There has been debate over whether people with the disease should convoy Rituxan as maintenance therapy after their initial chemotherapy. In the study, which was funded in part by F Hoffmann-La Roche, a pharmaceutical cast that sells Rituxan, roughly half of the 1019 participants took Rituxan, and the others did not. All formerly had taken the drug right after receiving chemotherapy.
In the next three years, the mull over found, people taking the drug took longer, on average, to lay open symptoms. Three-quarters of them made it to the three-year mark without progression of their illness, compared with about 58 percent of those who didn't pirate the drug. But the death rate over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.
Subscribe to:
Posts (Atom)